Syridex Bio

Syridex Bio is an impact-driven life sciences company and venture capital firm dedicated to addressing health disparities by investing in and accelerating the development of therapies for diseases that disproportionately affect underserved populations. Founded in 2022 and headquartered in Princeton, New Jersey, the firm focuses on therapeutic areas such as oncology, cardiology, and rare diseases. Syridex Bio employs a unique model that combines financial investment with strategic operational support to bring high-impact treatments to market. The company aims to bridge the gap in health equity by prioritizing clinical programs that have been historically underfunded or overlooked. By focusing on conditions like sickle cell disease and certain cancers, Syridex Bio seeks to improve medical outcomes for marginalized communities while generating sustainable returns.